Search
Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
go.drugbank.com/conditions/DBCOND0146855Drugs: PemetrexedSynonyms: Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationala significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by … gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics
Efonidipine
go.drugbank.com/drugs/DB09235InvestigationalEfonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_. … This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].
International brands: NZ-105Diazepam
go.drugbank.com/drugs/DB00829ApprovedIllicitInvestigationalVet approvedIts actions are mediated by enhancement of gamma-aminobutyric acid activity.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalIt was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management
Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigationalToremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative ...
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.
Piclidenoson
go.drugbank.com/drugs/DB05511InvestigationalIt is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.
Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnThese are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.